Neuren Pharmaceuticals NURPF Stock
Neuren Pharmaceuticals Price Chart
Neuren Pharmaceuticals NURPF Financial and Trading Overview
| Neuren Pharmaceuticals stock price | 8.88 USD |
| Previous Close | 8.88 USD |
| Open | 9.25 USD |
| Bid | 8.86 USD x 10000 |
| Ask | 9.44 USD x 20000 |
| Day's Range | 9.25 - 9.25 USD |
| 52 Week Range | 7.7 - 14.8 USD |
| Volume | 250 USD |
| Avg. Volume | 45 USD |
| Market Cap | 1.17B USD |
| Beta (5Y Monthly) | 1.561 |
| PE Ratio (TTM) | 54.411762 |
| EPS (TTM) | 0.17 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NURPF Valuation Measures
| Enterprise Value | 827.8M USD |
| Trailing P/E | 54.411762 |
| Forward P/E | 31.896553 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 18.099493 |
| Price/Book (mrq) | 4.851711 |
| Enterprise Value/Revenue | 12.805 |
| Enterprise Value/EBITDA | 37.522 |
Trading Information
Neuren Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 1.561 |
| 52-Week Change | 8.62% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 14.8 USD |
| 52 Week Low | 7.7 USD |
| 50-Day Moving Average | 8.63 USD |
| 200-Day Moving Average | 11.11 USD |
NURPF Share Statistics
| Avg. Volume (3 month) | 45 USD |
| Avg. Daily Volume (10-Days) | 0 USD |
| Shares Outstanding | 126.5M |
| Float | 109.68M |
| Short Ratio | N/A |
| % Held by Insiders | 13.38% |
| % Held by Institutions | 25.75% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | December 31, 2025 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 47.07% |
| Operating Margin (ttm) | 30.63% |
| Gross Margin | 43.70% |
| EBITDA Margin | 34.12% |
Management Effectiveness
| Return on Assets (ttm) | 3.66% |
| Return on Equity (ttm) | 8.66% |
Income Statement
| Revenue (ttm) | 64.65M USD |
| Revenue Per Share (ttm) | 0.5 USD |
| Quarterly Revenue Growth (yoy) | -80.90% |
| Gross Profit (ttm) | 28.26M USD |
| EBITDA | 22.06M USD |
| Net Income Avi to Common (ttm) | 30.44M USD |
| Diluted EPS (ttm) | 0.17 |
| Quarterly Earnings Growth (yoy) | -88.50% |
Balance Sheet
| Total Cash (mrq) | 296.12M USD |
| Total Cash Per Share (mrq) | 2.34 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 76.604 |
| Book Value Per Share (mrq) | 1.906544 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 125.42M USD |
| Levered Free Cash Flow (ttm) | 116.98M USD |
Profile of Neuren Pharmaceuticals
| Country | United States |
| State | VIC |
| City | Hawthorn East |
| Address | 117 Camberwell Road |
| ZIP | 3123 |
| Phone | 61 3 9092 0480 |
| Website | https://www.neurenpharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in preclinical trial stage for the treatment of Prader-Willi syndrome, Hypoxic Ischemic Encephalopathy, and SYNGAP1. The company was incorporated in 2001 and is based in Hawthorn East, Australia.
Q&A For Neuren Pharmaceuticals Stock
What is a current NURPF stock price?
Neuren Pharmaceuticals NURPF stock price today per share is 8.88 USD.
How to purchase Neuren Pharmaceuticals stock?
You can buy NURPF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Neuren Pharmaceuticals?
The stock symbol or ticker of Neuren Pharmaceuticals is NURPF.
Which industry does the Neuren Pharmaceuticals company belong to?
The Neuren Pharmaceuticals industry is Biotechnology.
How many shares does Neuren Pharmaceuticals have in circulation?
The max supply of Neuren Pharmaceuticals shares is 126.32M.
What is Neuren Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Neuren Pharmaceuticals PE Ratio is 52.20588300 now.
What was Neuren Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Neuren Pharmaceuticals EPS is 0.17 USD over the trailing 12 months.
Which sector does the Neuren Pharmaceuticals company belong to?
The Neuren Pharmaceuticals sector is Healthcare.